Obiettivo Since 2014, the revolution of immuno-oncology gives unprecedented hope for cure to cancer patients thanks to immunotherapies such as anti-PD(L)-1. However around 80% patients still don’t respond to anti-PD(L)-1. Several barriers are still to be overcome to sustain the path of a novel paradigm responding both unmet therapeutic needs and health economy sustainability; cancer being estimated as a leading cause of deaths in Europe (350’000 deaths in 2012– Globocan) corresponding to an economical burden of €126BN in total costsPDC*line Pharma develops a ground-breaking therapeutic vaccine platform using an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line); potentially doubling the response rate to anti-PD(L)-1 without additional toxicity, eliminating complex and costly process usually required by cell therapies.Our innovation project is aiming to establish the clinical proof of concept that PDC*lung, our leading candidate for lung cancer can induce strong anti-tumour immunity in patients. Lung cancer is of high priority for Europe since 1.9 million people are affected worldwide of which 340 000 in Europe (Globocan, 2012). It also represents an attractive market segment opportunity for PDC*line Pharma with an expected market growth of 4% per year: $6.1BN in 2013 to $8.6BN in 2023 worldwide (IMS, 2015). Campo scientifico scienze mediche e della salutemedicina clinicaoncologiacancro al polmonescienze socialiscienze politichetransizioni politicherivoluzioniscienze mediche e della salutemedicina di basefarmacologia e farmaciafarmacivacciniscienze mediche e della salutemedicina di baseimmunologiaimmunoterapiascienze mediche e della salutebiotecnologia medicatecnologie cellulari Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2016-2017 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore PDC LINE PHARMA Contribution nette de l'UE € 50 000,00 Indirizzo C/o gate1, petite halle 31 rue gustave eiffel 38000 Grenoble Francia Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Auvergne-Rhône-Alpes Rhône-Alpes Isère Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 21 429,00
